Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
ApexOnco Front Page
Recent articles
The company might have blown Enliven out of the water.
The battle intensifies as LY4170156 matches torvuta-S with activity in FRα <25% expresers.
But the ESMO discussant recommends against widespread use in hormone-sensitive disease.
Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.
The first TUB-040 data come just after Tubulis raised €308m.
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.
